Insider Trading April 14, 2026 09:06 AM

Buckle SVP of Sales Liquidates $887,761 in Shares as Stock Remains Near Year-Highs

Michelle Hoffman reduces holdings amid robust quarterly results and mixed analyst signals

By Ajmal Hussain BKE
Buckle SVP of Sales Liquidates $887,761 in Shares as Stock Remains Near Year-Highs
BKE

Michelle Hoffman, Senior Vice President of Sales at Buckle Inc (BKE), sold 16,200 shares on April 10, 2026, for roughly $887,761 and later gifted 10,000 shares on April 13, 2026. The transactions occurred while BKE traded near $54.49 after a 68% rise over the prior year. The company posted stronger-than-expected Q4 FY2025 results, and analysts have adjusted targets while noting limited near-term EPS growth.

Key Points

  • Michelle Hoffman sold 16,200 Buckle shares on April 10, 2026, at $54.8001 per share, totaling about $887,761, and later gifted 10,000 shares on April 13, 2026.
  • Buckle exceeded Q4 FY2025 expectations with EPS of $1.60 versus $1.53 expected and revenues of $399.1 million versus $396.45 million expected; comparable store net sales rose 7.0% for the five-week period ending April 4, 2026.
  • Analysts show mixed signals: InvestingPro indicates the stock is slightly overvalued but notes an 8.07% dividend yield and strong fundamentals, while UBS lowered its price target to $53 (from $55) but maintained a Neutral rating due to limited near-term EPS growth.

Michelle Hoffman, who serves as Senior Vice President of Sales at Buckle Inc (NYSE: BKE), moved to reduce her stake in the company in April 2026. On April 10, 2026, Hoffman sold 16,200 shares of common stock at a price of $54.8001 per share, producing proceeds of approximately $887,761. At the time, Buckle shares were trading near $54.49, after recording a 68% gain over the previous 12 months.

Following that disposition, Hoffman retained direct ownership of 29,682 Buckle shares. A few days later, on April 13, 2026, she disposed of another 10,000 shares, with that later transfer recorded as a gift.

The insider activity comes against a backdrop of solid financial performance for Buckle. For the fourth quarter of fiscal 2025 the company reported earnings per share of $1.60, ahead of the $1.53 analysts had expected. Quarterly revenues were $399.1 million, slightly above the consensus forecast of $396.45 million.

Operationally, Buckle reported strength in its March fiscal period and early April trading. For the five-week period ending April 4, 2026, comparable store net sales rose 7.0% year-over-year. Total net sales for the March fiscal period increased 8.2% to $118.0 million from $109.1 million in the prior year.

Market commentary has been mixed. UBS revised its price target on Buckle to $53 from $55 while keeping a Neutral rating on the shares. The firm cited a constrained outlook for near-term earnings-per-share growth even as it acknowledged Buckle’s solid long-term strategy.

Separately, InvestingPro analysis flagged the stock as slightly overvalued relative to its Fair Value metric, while noting an attractive dividend yield of 8.07% and strong underlying fundamentals. The platform also references additional tips and a Pro Research Report for investors seeking deeper analysis.


These recent disclosures and results present a combination of insider liquidity, continued revenue and earnings outperformance, and measured analyst caution - all relevant inputs for investors evaluating Buckle’s current valuation and income appeal.

Risks

  • Insider selling could be perceived negatively by investors assessing confidence in management - this affects investor sentiment in the equities market.
  • Analyst revision of price targets and cautious comments on near-term EPS growth may pressure valuation expectations for Buckle shares in the short term.
  • InvestingPro’s assessment that the stock is slightly overvalued introduces uncertainty for value-focused investors despite a high dividend yield.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026